Date: 08-Aug-2019

Novartis says knew about Zolgensma data problems before U.S. approval

New York: Drugmaker Novartis on Wednesday acknowledged that there were discrepancies with data it had submitted to regulators for approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed its internal investigation. Novartis faces possible civil or criminal penalties from the U.S. Food and Drug